Company intelligence / Profile preview

Rubicon Science

Irvine, California, United Statesrubiconscience.com.au ↗

Ownership: Private
Employees: ~9
Development stage: Other

Overview

Rubicon Biotechnology is developing two main biologic platforms. The Fv-Hsp72 fusion protein targets stressed/dying cells to deliver Hsp72, aiming to reduce cell death in acute conditions like myocardial infarction and stroke. The Modified Annexin platform uses a non-internalizing annexin A5 variant to target phosphatidylserine on tumor cells and vasculature, enabling delivery of anti-cancer agents. Both programs are currently at the preclinical or discovery stage with no reported clinical trial results yet[2][5].

Therapeutic areas: PulmonologyCardiovascularOncology
Modalities: Fusion proteinSingle-chain FV antibody fragmentBiological products (general category)
Industry: Biotech

Partnerships

No major pharmaceutical or biotech partnerships publicly disclosed as of June 2025.

Beyond the preview

Go deeper on Rubicon Science.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Rubicon Science.

Explore the full profile